Clinical Trial Update: Safety and Efficacy of T Cell Genetic Immunotherapy for HIV [Phase 2]

View source ↗

Summary

A Phase 2 trial update from VIRxSYS Corporation evaluating the safety and efficacy of a T cell genetic immunotherapy for HIV.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• T cell genetic immunotherapy for HIV

Snippet

Sponsor: VIRxSYS Corporation | Conditions: HIV Infection | Phase 2 | Status: UNKNOWN